| Pham, Mirko |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
Tension, NCT03094715: Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window |
|
|
| Terminated | N/A | 253 | Europe, Canada, RoW | Thrombectomy, Mechanical thrombectomy, Best medical care, Control group | University Hospital Heidelberg, Karolinska University Hospital, Eppdata GmbH Hamburg, Germany, Aarhus University Hospital, Medical University Innsbruck, Groupe Hospitalier Pitie-Salpetriere, Oslo University Hospital, University Hospital, Martin, Charles University, Czech Republic, Hospices Civils de Lyon, CHU de Reims, Epidemiological and Clinical Research Information Network, STROKE ALLIANCE FOR EUROPE, International Consortium for Health Outcome Measurement, Inc., Europan Society for Minimally Invasive Neurological Therapy, Universitätsklinikum Hamburg-Eppendorf | Stroke, Acute, Cerebral Stroke, Cerebrovascular Stroke, Apoplexy; Brain | 05/23 | 11/23 | | |
| Ehmer, Ursula |
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function |
|
|
| Completed | 2 | 40 | Europe | Cabozantinib Oral Tablet, CABOMETYX | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan | Hepatocellular Carcinoma (HCC), Second Line Treatment | 10/24 | 10/24 | | |
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab |
|
|
| Recruiting | 2 | 106 | Europe | Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE) | Ludwig-Maximilians - University of Munich | Hepatocellular Carcinoma Non-resectable | 03/25 | 03/25 | | |
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC |
|
|
| Recruiting | 2 | 55 | Europe | Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School | Hepatocellular Carcinoma Non-resectable, HCC | 03/25 | 09/25 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
MONTBLANC, NCT05844046: Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients |
|
|
| Recruiting | 2 | 83 | Europe | durvalumab, tremelimumab, bevacizumab | Enrico De Toni | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
| Kandulski, Arne |
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab |
|
|
| Recruiting | 2 | 106 | Europe | Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE) | Ludwig-Maximilians - University of Munich | Hepatocellular Carcinoma Non-resectable | 03/25 | 03/25 | | |
| Reiter, Florian |
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab |
|
|
| Recruiting | 2 | 106 | Europe | Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE) | Ludwig-Maximilians - University of Munich | Hepatocellular Carcinoma Non-resectable | 03/25 | 03/25 | | |
MONTBLANC, NCT05844046: Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients |
|
|
| Recruiting | 2 | 83 | Europe | durvalumab, tremelimumab, bevacizumab | Enrico De Toni | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
